QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Summary by Relevant Sections Company Overview - uniQure N.V. is facing allegations of violating federal securities laws by making false or misleading statements regarding its Pivotal Study and the approval status of its BLA submission for AMT-130 [1] Legal Proceedings - The complaint alleges that the design of uniQure's Pivotal Study was not fully approved by the FDA, and that the company downplayed the likelihood of needing to delay its BLA timeline for additional studies [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to a significant drop in share price [1] Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]